In an attempt to synthesize a photoreactive geranylcysteine derivative, A, with an appropriate photoprobe to be studied as a mimic for farnesylated protein, B, the following syntheses were carried out. The hydroxyl group of geraniol was protected with DHP/PPTs to generate 1 (98.1%). Allylic oxidation of 1 by using TBHP/SeO2 yielded 2 (31.5%). A modified oxidation increased the yield of 2 (34.4%). Treatment of 2 with BTC/pyridine afforded 3 (86.0%). Reaction of 3 with NaN3/DMF gave 8 and 9 (49.4%). Deprotection of this mixture under PPTs/EtOH afforded 10 and 11 (64.1%). Because of the unexpected reaction of 3 with N3-, we focused on alternative target molecules 12 and 13 (Figure 7). Our attempts to synthesize the first intermediates 14 and 15 in the syntheses of 12 and 13 (Scheme 14 and Scheme 15) have resulted in the isolation of the unreacted starting material.

La prénylation de type I des protéines correspond à une modification post-traductionnelle faisant intervenir une liaison thioéther entre une cystéine localisée dans un motif CaaX en position C terminale et un groupement prényle en C 15 (farnésyle) ou C 20 (géranylgéranyle). Ces réactions sont catalysées par des protéine prényltransférases (PPTs) appartenant à la même famille fonctionnelle et comprenant la protéine farnésyltransférase (PFT) et géranylgéranyltransférase de type I (PGGT-I). Les plantes se distinguent par une double origine des substrats prényle (farnésyle diphosphate et géranylgéranyle diphosphate) utilisés comme précurseurs pour la biosynthèse des isoprénoïdes. Ces derniers sont biosynthétisés par l'intermédiaire de deux voies métaboliques distinctes, la voie cytosolique du mévalonate (MVA) et la voie plastidiale du méthylérythritol phosphate (MEP). Il est maintenant clair que la géranylgéranylation des protéines végétales dépend de la voie du MEP. Durant ce travail de thèse doctorale une étude comparative des spécificités de substrat a été réalisée. Elle a permis de montrer que la PFT est spécifique de son substrat protéique alors que la PGGT-I est spécifique de son substrat prényle. Ces spécificités peuvent néanmoins être modifiées in vivo, par exemple lors d’une augmentation de la concentration en MVA, suggérant que cette flexibilité des propriétés enzymatiques a un rôle régulateur dans certaines conditions physiologiques. Pour cette raison, nous avons entrepris une caractérisation de la prénylation des protéines dans des plantes de tabac élicitées, qui induisent la synthèse de MVA pour produire le capsidiol, une phytoalexine sesquiterpénique. La biosynthèse de ce métabolite secondaire capsidiol dérivant de la voie du MVA, est dépendante de la prénylation des protéines, notamment de protéines géranylgéranylées d’origine plastidiale. Le monoterpène S-carvone a été identifié comme un inhibiteur de la biosynthèse de capsidiol en interférant avec l’activité des PPTs in vivo. Les travaux ont également permis d’envisager l’existence d’un nouveau mode de prénylation des protéines spécifique aux feuilles. / Type-I protein prenylation is a post-translational modification of a protein bearing a CaaX motif with a prenyl moiety, this by a thioether linkage. The enzymes catalyzing those reactions are called protein prenyltransferase (PPTs). Two enzymes are involved, the protein farnesyltransferase (PFT) and the protein geranylgeranyltransferase type I (PGGT-I). They respectively use farnesyl diphosphate and geranylgeranyl diphosphate as substrate. Those precursors are synthetized in plants by two differentbiosynthetic pathways: the cytosolic mevalonate (MVA) and the plastidial methylerythritol phosphate (MEP) pathways. Protein geranylgeranylation is dependent of the MEP pathway. Those specificities can be modified A comparative analysis of PPTs specificity was done during this PhD thesis, revealing that PFT is specific for its protein substrate, while PGGT-I is specific for its prenyl substrate. But those specificities can be modulated in vivo, for instance by increasing the concentration of MVA. This suggests that the regulation of protein prenylation specificities can become functionally important during physiological processes. For that reason we characterized protein prenylation in elicited tobacco plants, which produce the sesquiterpene phytoalexin capsidiol. This metabolite is synthesized via the MVA pathway, and this process depends of protein prenylation, in particular geranylgeranylation, with the substrate coming from plastids. S-Carvone, a monoterpene, was identified as an inhibitor of PPTS, resulting in a lack of capsidiol production. This work also suggests that a new mechanism of prenylation might exist, specifically in leaves.

Dissertation (Ph.D.)--University of South Florida, 2008. / Includes vita. Also available online. Includes bibliographical references.

Overall survival of the metastatic forms of epithelial derived cancers, especially head and neck squamous cell carcinomas (HNSCC), has not significantly improved even with the application of aggressive combined modality approaches incorporating radiation and chemotherapy. Cumulative evidence implicates the epidermal growth factor receptor (EGFR) as an important therapeutic target in HNSCC. We have previously demonstrated that the combination of lovastatin, a potent inhibitor of the mevalonate pathway, with EGFR tyrosine kinase inhibitors induced robust synergistic cytotoxicity. However, the use of high dose statins in our clinical trial was associated with significant toxicities including higher than anticipated rate of muscle pathologies. Our goal was to uncover novel downstream targets of the mevalonate pathway that may enhance the efficacy or limit toxicities of this novel combination therapeutic approach. In this study we have demonstrated that GGTI-298, an inhibitor of protein geranylgeranylation, through its ability to disrupt the actin cytoskeleton, inhibits EGFR dimerization and cellular trafficking. This novel mechanism targeting the EGFR has clinical implications as GGTI-298 in combination with tarceva, a clinically relevant EGFR inhibitor, showed enhanced cytotoxicity and inhibitory effects on EGFR activation and its downstream signaling.

Dissertation (Ph.D.)--University of South Florida, 2008. / Title from PDF of title page. Document formatted into pages; contains 187 pages. Includes vita. Includes bibliographical references.

Overall survival of the metastatic forms of epithelial derived cancers, especially head and neck squamous cell carcinomas (HNSCC), has not significantly improved even with the application of aggressive combined modality approaches incorporating radiation and chemotherapy. Cumulative evidence implicates the epidermal growth factor receptor (EGFR) as an important therapeutic target in HNSCC. We have previously demonstrated that the combination of lovastatin, a potent inhibitor of the mevalonate pathway, with EGFR tyrosine kinase inhibitors induced robust synergistic cytotoxicity. However, the use of high dose statins in our clinical trial was associated with significant toxicities including higher than anticipated rate of muscle pathologies. Our goal was to uncover novel downstream targets of the mevalonate pathway that may enhance the efficacy or limit toxicities of this novel combination therapeutic approach. In this study we have demonstrated that GGTI-298, an inhibitor of protein geranylgeranylation, through its ability to disrupt the actin cytoskeleton, inhibits EGFR dimerization and cellular trafficking. This novel mechanism targeting the EGFR has clinical implications as GGTI-298 in combination with tarceva, a clinically relevant EGFR inhibitor, showed enhanced cytotoxicity and inhibitory effects on EGFR activation and its downstream signaling.

The nuclear lamina protein, lamin A is produced by proteolytic cleavage of a 74 kDa precursor protein, prelamin A. The conversion of this precursor to mature lamin A is mediated by a specific endoprotease, prelamin A endoprotease. Subnuclear fractionation indicates that the prelamin A endoprotease is localized at the nuclear membrane. The enzyme appears to be an integral membrane protein, as it can only be removed from the nuclear envelope with detergent. It is effectively solubilized by the detergent n-octyl-beta-D-glucopyranoside and can be partially-purified (approximately 1200-fold) by size exclusion and cation exchange (Mono S) chromatography. Prelamin A endoprotease from HeLa cells was eluted from Mono S with 0.3 M sodium chloride as a single peak of activity. SDS-PAGE analysis of this prelamin A endoprotease preparation shows that it contains one major polypeptide at 65 kDa and smaller amounts of a second 68 kDa polypeptide. Inhibition of the enzyme activity in this preparation by specific serine protease inhibitors is consistent with the enzyme being a serine protease.